Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate
LTG-001 achieved the primary endpoint of the Phase IIb LTG-001-010 trial (NCT07102459) by achieving better-than-placebo scores in the time-weighted sum of the pain-intensity difference (SPID) over the 48-hour treatment period (SPID48), based on the 0-10 range of scores of the Numeric Pain Rating Scale, with higher SPID48 values indicating greater pain reduction. The post Latigo Reports Positive…
We haven't written up this one. GEN Biotechnology has the full story — the link below goes straight to it.
